Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688556 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 745
- Enrollment target
NCT02688556: Completed Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT02688556 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 745 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688556, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 745 participants
- Enrollment target
Study Summary
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.
Primary Outcome
Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score
Interventions
- DRUG cyclosporine
- DRUG vehicle of OTX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 745 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT02688556 record still lists
NCT02688556 is an interventional study that assigns participants to a tested intervention. The registered 745 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT02688556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02688556 about?
NCT02688556 is a clinical study titled "Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca". This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.
What is the current status of trial NCT02688556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 745 participants. The study started on 2016-02. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02688556?
The interventions under investigation include: cyclosporine (DRUG), vehicle of OTX-101 (DRUG).
Who is sponsoring clinical trial NCT02688556?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02688556's enrollment target sits among peer trials
745 475th of 2000 higher than 1,526 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia